AAN Conference Perspectives - Episode 2
Chris O’Brien, MD, discusses the frequency of tardive dyskinesia in the United States and the availability of the first treatment for the disorder: valbenazine (Ingrezza). O'Brien discussed this information at the 69th American Academy of Neurology Annual Meeting.
O’Brien, chief medical officer, Neurocrine Sciences, Inc., discusses the frequency of tardive dyskinesia, which affects more than 500,000 individuals in the United States.
Prior to the recent US Food and Drug Administration’s approval of valbenazine (Ingrezza), there was no approved therapy for tardive dyskinesia; the patients were only looked at, not treated, O’Brien said.